MedTrace Logo

Study to Evaluate Imatinib in Desmoid Tumors

NCT01137916 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2017-05-03

No results posted yet for this study

Summary

The objective of the present study is to evaluate the activity and safety of imatinib in patients with aggressive fibromatosis who, after receiving the standard therapy, show an inoperable recurrent tumor or disease not readily controllable by surgery or radiotherapy.

Conditions

  • Aggressive Fibromatosis
  • Desmoid Tumor

Interventions

DRUG

Imatinib

800 mg

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Bernd Kasper, PD Dr. med. · University of Heidelberg, Mannheim University Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01137916 on ClinicalTrials.gov